Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54
Rieke Alten, Bogdan Batko, Tomas Hala, Hideto Kameda, Sebastiao C Radominski, Vira Tseluyko, Goran Babic, Carol Cronenberger, Sarah Hackley, Muhammad Rehman, Oliver von Richter, Min Zhang, Stanley Cohen
RMD Open Mar 2019, 5 (1) e000876; DOI: 10.1136/rmdopen-2018-000876